SOFT beta -ADRENERGIC BLOCKING AGENTS

Abstract: New soft beta -adrenergic blocking agents, useful in the treatment or prevention of cardiovascular disorders and in the treatment of glaucome, have formula (I), wherein n is an integer from 0 to 10; R is C6-C12 cycloalkyl-CpH2p-, C6-C18 polycycloalkyl-CpH2p-, C6-C18 polycycloalkenyl-CpH2p- or C6-C12 cycloalkenyl-CpH2p- (wherein p is 0, 1, 2 or 3), or together with the adjacent group (II) represents a variety of other complex ester groupings; R1 is C1-C7 alkyl; and Ar is a divalent radical containing al least one aromatic nucleus. The corresponding pharmaceutically acceptable acid addition salts are also described.

Description: SOFT β -ADRENERGIC BLOCKING AGENTS Field of the Invention: The * present invention provides novel compounds containing at least one aromatic nucleus which are soft e-adrenergic blocking agents, useful in the treatment or prevention of cardiovascular disorders and in the treatment of glaucoma. Background of the Invention: Many β-adrenergic blocking agents are known and used; unfortunately, however, these agents are generally subject to facile oxidative metabolic degradations. Many of the metabolites also possess significant 3-blocking activity and, due to their different pharmacokinetic properties, make dosing and optimi¬ zation of therapy difficult. The metabolites of bufuralol, for example, have longer biological half- lives than the parent drug. . Francis et al , Biomed. Mass. Spectrometry, _3, 281-285 (1976). Consequently, it is difficult to determine an adequate dose of the known β-blockers for administration, especially when administering them therapeutically to patients suffering fron angina, pectoris, hypertension or un¬ expected arrhythmias during surgical operations. It would be most desirable to design β-blockers which would be metabolized in a simple, predictable and controllable manner in one step to an inactive meta¬ bolite, regardless of the conditions of the patient and other drugs used. This would necessitate, how¬ ever, avoiding oxidative metabolism. -1 - The present inventor has previously devised a general soft drug approach having such objectives, one specific aspect of that approach being the in¬ active metabolite method. Bodor, Proceedings of the 2nd IUPAC-IUPHAR Symposium on Strategy in Drug Re¬ search, Noordwi kerhout, J.A. Keverling Buis an (ed.), Else.vier Scientific Publishing Company, Amsterdam, 1982; Bodor, Belgian Patent No. 889,563, 03 November 1981; Chem. Abstr. 97:6651n (1982). The principles of the inactive metabolite approach are: _ l ) Start the design process with a known in¬ active metabolite of a drug. (2) Alter the metabolite to obtain a structure that resembles (isosteric and/or isoelectronic) the starting or an analogous drug. (3) Design the structure and metabolism of the new soft compound in such a way as to yield the starting inactive metabolite in one step without going through toxic intermediates. (4) Control transport and binding properties as well as the rate of metabolism and pharmacokinetics by molecular manipulations in the activation stage. However, it is not necessary to wait for an inactive metabolite to be isolated; it may be possible to design the inactive metabolite during the general drug design process based on knowledge of structural requirements for activity as well as elimination and enzymatic cleavage. Recently, American Hospital Supply Corporation's International Application No. PCT/US81/01514, published under International Publication No. W082/01869 on 10 June 1982, described a series of short acting β-adrenergic blocking compounds containing ester moities which are structurally related to some of the compounds of the present invention. The PCT application does not, however, appear to address the problem addressed by the present invention, i.e. how to design β-blockers which would be metabolized in one simple, predictable, controllable step to an inactive metabolite while avoiding oxidative metabolism ; moreover, the esters of the PCT application are generally less complex than those described herein below. See also Erhardt et al, j j. Me^. Chem., 25_, 1408-1412 (1982). Similar simple alky! esters were described much earlier, e.g. Barrett et al United States Patent No. 3,663,607, issued 16 May 1972. See also Japanese Patent Application No. 230664/1982, filed 27 December 1982. Summary and Objects of the Invention: In view with the foregoing, it is an object of this invention to provide a new class of ø-adrenergic agents which will be metabolized in a simple, pre¬ dictable and controllable manner in one step to an inactive metabolite. It is another object, of the present invention to provide new β-adrenergic agents which are not subject to significant oxidative meta¬ bolism. It is another object of this invention to apply the present inventor's general inactive meta¬ bolite approach to the design of novel soft ø-blockers. These and other objects of the present invention are achieved by providing compounds of the formula CH 2 NHR 1 (I) wherei n : n is an integer from 0 to 10 inclusive; R is Cg-C 12 cycloalkyl-C H 2 - wherein p is 0, 1. 2 or 3; C 8 -C 18 polycycloalkyl-C H 2 - wherein p is defined as above; Cg-C^ o po ycycloalkenyl-C H * 2 - wherein p is defined as above; Cg-C- j? cycloalkenyl - C . wherein p is defined as above; -CH 2 -X-R 2 wherein X is S, SO or S0 2 and R 2 is C 1 -C 7 alkyl or C 3 -C 12 cyclo- + a wherein R 2 is defined as above; - X is defined as above, and wherein R l and R 4 is C j -^ alkyl or wherein R^ and R^ taken together represent -(CH 2 ) - wherein m is 3 or 4 and -( H 2 ) m - is optionally substituted by one to three C-^-C j alkyl; -CH-OCORg wherein Rg is hydrogen or C 1 -C 7 alkyl and R g is unsubstituted or substituted C- -C- j alkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl or C 2 -Cg alkenyl, the substituents being selected from the group consisting of halo, C,-C 7 alkoxy, C r C 7 alkylthio, -Cy alkylsulfinyl , C -C 7 alkylsul- 0 0 fonyl, -NHC-(C 1 -C 7 alkyl) and -0C-(C 1 -C 7 alkyl), or Rg is unsubstituted or substituted phenyl or benzyl, the substituents being selected from the group con¬ sisting of C χ -C 7 alkyl, Cj-C 6 alkoxy, halo, carbamc-yl, C 2 -Cg alkoxycarbonyl, C 2 -C 8 alkanoyloxy, 0-, -C-j halo- alkyl, mono(C 1 -C 7 alkyl)amino, di(C χ -C 7 alkyl)amino, mαno(C 1 -C 7 alkyl )carbamoyl , di(C χ -C 7 alkyl Jcarba oyl , C χ -C 7 alkylthio, C ^C alkylsulfinyl and C χ -C 7 i b a l kyl su l fonyl ; -CH-C00Rg whe re i n R g and R g a re de - fs fined as above; or -CH-CONR 7 Rg wherein R g is defined as above and R 7 and R Q , which can be the same or dif¬ ferent, are each hydrogen, C^-Cy alkyl, C 3 -C 1 cyclo- alkyl, phenyl or benzyl, or R 7 and Rg are combined such that - R 7 Rg represents the residue of a satu¬ rated monocyclic secondary amine; s c r c 7 alkyl and Ar is a divalent radical containing at least one aromatic nucleus ; with the proviso that when the divalent radical represented by Ar is unsubstituted phenylene, then R cannot be C 8 -C, 2 cycloalkyl-C H 2 - wherein p is defined as above. The compounds of the present invention avoid the disadvantages of many known β-blockers resulting from their active metabolites. The compounds of formula (I) are rationally designed so that when administered to a mammal they are subjected to an enzymatic hydrolytic (i.e. esterase) process which is much faster than oxidative metabolism and which leads to hydrolyzed metabolites which possess vary little or no β-adrenergic activity. Thus, for example, in the case of a group of preferred metoprolol derivatives of the invention, such are designed to hydrolytically deactivate to the phenylacetic acid derivative, i.e. the compound of the formula O - CH 2 C00H, -S- which is an inactive metabolite of metoprolol and the major metabolite found in the urine. [See, for example, Borg et al , Acta Pharmacol. Toxicol., 36 (Suppl. V), 125-135 (1975).] The rate of hydrolysis deactivation may be controlled by the structure of the esters. Accordingly, the compounds of the present in¬ vention exhibit excellent β-blocking efficacy without adverse side effects for a certain duration, dependent only on the hydrolytic metabolism rate. As a con¬ sequence, it is easy to control and maintain adequate therapeutic action with a desirable onset time using the present compounds. The onset time is usually short compared with conventional β-adrenergic blocking agents; therefore, the instant compounds are expected to be of particular use in the treatment of arrhythmias ischemic heart disease and hypertension, possibly attending surgical operations. The instant compounds are also expected to be. of special value when used in the treatment of glaucoma, since they will not only reduce intraocular pressure when applied locally to the eye, but because of their ' "soft" nature will de¬ activate during absorption and thus avoid the typical β -blocker systemic side effects which attend use of known β-blockers for this purpose. -7- Detailed Description of the Invention: With respect to the various groups encompassed by the generic terms used in this specification, the following definitions and explanations are applicable The divalent radicals containing at least one aromatic nucleus which are represented by Ar can be unsubstituted or substituted monocyclic or polycylic ring systems and may include hetero ring atoms, par¬ ticularly N and 0. Illustrative divalent radicals represented by Ar include the following: (1) phenylene, i.e. a radical of the formula especially 1,4-phenylene and 1,3-phenylene, optionally bearing one or more substituents such as C,-C 7 alkyl, e.g. CH 3 CH 2 - or CH 3 -; C j -^ alkyl-O-C-J-C-J alkylene-, e.g. -CH 3 0CH 2 CH 2 -; C 2 -Cg alkenyl, e.g. CH 2 =CH-CH 2 - ; C-C-7 alkyl-S-, e.g. CH 3 -S-; C 2 -Cg alkenyl-0-, e.g. CH 2 CH=CH 2 -0-; C 3 -C, 2 cycloalkyl, e.g. cyclopentyl ; C 1 -C 7 alkyl-CONH-, e.g. CH 3 CH 2 CH 2 C0NH- or CH 3 C0NH-; C j -C-j alkyl-CO-, e.g. CH 3 C0-; and/or HgNCO-C j -^ alkylene-; e.g. H 2 NC0-CH 2 -; (2) divalent fused ring systems containing two or three rings, optionally containing one or two N, S or 0 ring atoms, such as: especially (c) especially especial ly and (3) divalent aryl-alkylene-aryl systems, e.g. phenylene-C j --Cg alkylene-phenyl radicals such as -10 - Preferably, the divalent radical represented by Ar 0 'I . is selected such that the R0C-C n H 2n - grouping in formula (I) either simply replaces a hydrogen atom in the corresponding ring of a known β-blocker or replaces a non-critical ring substituent in the corresponding known β-blocker, e.g. a lower alkyl, lower alkyl- 0-lower alkylene-, lower alkyl-CONH- or H 2 NC0-lower alkylene- substituent. Particularly preferred compounds of the invention bear such a structural relationship to metoprolol, bufuralol, alprenolol, bunolol, xipranolol, nadolol, tiprenolol, oxprenolol, penbutolol, pindolol, carteolol, propranolol, acebutolol, atenolol and practolol. The alkyl, alkenyl and alkylene groupings encom¬ passed by any of the structural variables in formula (I) can be straight or branched-chain groups con¬ taining the indicated number of carbon atoms. The term "lower" used in conjunction with such radicals ' indicates that they may contain up to 7 carbon atoms. Specific examples of alkyl radicals encompassed by formula (I), whether as specific values for R, or as a portion of an R or Ar group, include methyl, ethyl , propyl , butyl , pentyl , hexyl and heptyl and their branched-chain isomers, e.g. isopropyl, isobutyl and tert-butyl. Preferred values for R χ are isopropyl and tert-butyl . The alkenyl radicals encompassed by various R and Ar values can be exemplified by vinyl, propenyl and butenyl and the branched-chain groups having 3 or more carbon atoms. The alkylene moieties encompassed by C-.H 2n (when n is other than zero) as well as those encompassed by various values for R and Ar are typified by methylene, ethylene, trimethylene, 2-methyltrimethylene, 2,2- dimethyltri ethylene, 1-methyltrimethylene, methyl- methylene, ethyl ethylene, tetramethylene, penta- methylene, hexamethylene and the like. The alkoxy, alkylthio, alkysulfinyl , alkylsulfonyl , alkoxycarbonyl , alkanoyloxy, monoalkylamino, dialkyl- amino, monoalkylcarbamoyl and dialkylcarbamo ' yl groupings are of the type -0-alkyl -S-alkyl -SO-alkyl -S0 2 -alkyl -C-0-alkyl 0 -O-C-alkyl II J 0 -NH-alkyl 12- -C-NH-alkyl H 0 alkyl and 0 alkyl respectively, wherein alkyl is as hereinbefore defined and exemplified. The halo substituents can be chloro, bromo, iodo or fluoro. The haloalkyl substituents can be mono- haloaTkyl or polyhaloalkyl, straight or branched- chain, substituted with from 1 to 3 halogen atoms, the term "halogen" as used herein including chlorine, bromine, iodine or fluorine. Specific examples of the contemplated monohaloalkyl and polyhaloalkyl groups include chloromethyl , dichloro ethyl , trichloro ethyl , bro omethyl, fluoro ethyl , difluoromethy , trifluoro- methyl, 1-fluoroethyl , 1-chloroethyl , 2-chloroethyl , 2,2,2-trichloroethyl, 2,2,2-trifluoroethyl , 1,2-dichloro- ethyl, 1-chloropropyl , 3-chloropropyl , 1-ch orobutyl , 1-chloropentyl , 1-chlorohexyT, 4-chlorobutyl and the like. When R in formula (I) is C -C, 2 cycloalkyl-C H 2 -, the cycloalkyl groups contain 6 to 8 ring atoms and may optionally bear one or more, preferably one to four, alkyl substituents. Exemplary such cycloalkyT groups are cyclohexyl, 2,6-dlmethy.cyclohexyl, 3,3,5,5-tetra- ethylcyclohexyl , 2-methylcyclohexyl , 2-ethylcyclohexyl , 4-propylcyclohexyl , 5-butyl cyclohexyl , 2 ,3-dimethyl - cyclohexyl, 2 ,4-dimethylcyclohexyl , 2 ;5-dimethyl - cyclohexyl, 2,3,4-trimethylcyclohexyl , 2 ,3-dimethyl - 5-ethylcyclohexyl , 2,5-dimethy1 -6-ρroρylcyclohexyl , 2,4-dimethyl-3-butylcyclohexyl, 2, ,4 ,4-tetramethyl - cyclohexyl, 3,3 ,6,6-tetramethylcyclohexyl , 3,3,4,5,5- pentamethylcyclohexyl , 3 ,3,4,5,5 ,6-hexamethylcyclohexyl , 3,3,5-trimethy1-4-ethyl cyclohexyl , 3,4 ,4 -trimethyl - 5-propylcyclohexyl , cycloheptyl, 3-methyl cycloheptyl , 5-propylcycloheptyl , 6-butylcycloheptyl , 7-methyl cyclo¬ heptyl , cyclooctyl, 2-methylcyclooctyl , 3-ethylcycl ooctyl , 3,3,4-trimethylcyclooctyl , 3,3 ,5 ,5-tetramethylcyclooctyl and the like. Among the presently preferred cycloalkyl- C H ? -groups represented by R are cyclohexyl , 2,6- P y < P dimethyl cyclohexyl and 3 ,3,5 ,5-tetramethy.l cycl ohexyl . Thus, when R is cycl oal kyl - C H 2 -, p is preferably zero or one, most preferably zero. When a. cycloalkyl radical is present ' in formula (1) as a portion of Ar or as a different portion of R (e.g when R is -CH 2 -X-R 2 wherein R 2 is C 3 -C χ2 cycloalkyl), then such a cycloalkyl radical can contain 3 to 8 ring atoms and may optionally bear one or more, pre¬ ferably one to four, alkyl substituents. Examples of such cycloalkyl groups include the examples of C 6" C 12 cy lo^kyl radicals recited above as well as the lower homologues, e.g. cyclopropyl, 2-methyl- cyclopropyl, 3-ethylcyclopropyl , 2-butyl cyclopropyl , 3-pentylcyclopropyl , 2-hexylcyclopropyl , cyclobutyl , 2-methylcyclobutyl , 2,3-dimethylcyclobutyl , 3-butyl- cyclobutyl, 4-hexylcyclobutyl, ,3,3-trimethylcyclobutyl , 3,3,4,4-tetramethylcyclobutyl, cyclopentyl, 2-methyl- cyclopentyl, 3-ethylcyclopentyl , 4-butyl cyclopentyl , 5-methylcyclopentyl , 3-pentylcyclopentyl , 4-hexyl- cyclopentyl, 2,3-dimethylcyclopentyl , 2 ,2 ,5 ,5-tetra- -14 - methylcyclopentyl , 2,3,4-trimethylcyclopentyl , 2,4- dimethyl-3-ethylcyclopentyl , 2,2,3,4,4-pentamethyl - cyclopentyl, 2,3-dimethyl-3-propylcyclopentyl and the like. When a cycloalkenyl radical is present in formula 5 (I) as a portion of R, corresponding unsaturated radicals such as cyclopentenyl and cyclohexenyl and the like are contemplated (depending, of course, on the carbon atom limitations in the generic definitions). Again, when R is ~ - ~t - - cycloalkyl- ^ C H 2 -, p is pre- 10 ferably zero or one, most preferably zero. The polycycloalkyl-C H 2 - radicals represented by R are bridged saturated alicylic hydrocarbon systems consisting of two or more rings, optionally bearing one or more alkyl substituents and having a total of 15 6 to 18 carbon atoms in the ring portion. The cor¬ responding bridged unsaturated alicyclic hydrocarbon systems are intended by the term "C -C 18 polycyclo- alkenyl-C H 2 -". Such polycycloalkyl and polycyclo- alkenyl radicals are exemplified by adamantyl (especially 20 1- or 2- adamantyl), adamantylmethyl (especially 1- adamantylmethyl ), adamantylethyl (especially 1- adamantyl ethyl), bornyl , norbornyl (e.g. exo-norbornyl or eπdo- norboryl), norbornenyl (e.g. 5-norbornen-2-yl ) , norbornyl ethyl (e.g. 2-norbornyimethyl ) and 25 πorbornylethyl (e.g. 2-norbornylethyl ). Thus, in the case of polycyclic radicals, p is preferably 0, 1 or 2. ?5 When R in formula (I) is -CH-C0NR 7 R g wherein ' 30 "NR 7 R 8 ^Presen s the residue of a saturated monocyclic secondary a ine, such onocycles preferably have 5 to 7 ring atoms optionally containing another hete ' ro 15- atom (-0-, -S- or -N-) in addition to the indicated nitrogen atom, and optionally bear one or more sub¬ stituents such as phenyl , benzyl and methyl. Illustrative of residues of saturated monocyclic secondary amines which are encompassed by the -NR 7 g term are morpholino, 1-ρyrrolidinyl , 4-benzyl-l- piperazinyl, perhydro-l,2,4-oxathiazin-4-yl , 1- or 4-piperazinyl , 4-methyl-l-piperazinyl , piperidino, hexamethyleneimino, 4-phenylpiperidino, 2-methyl- 1-pyrazolidinyl , 1- or 2-pyrazol idinyl , 3-methyl- 1-imidazol idinyl , 1- or 3-imidazol idinyl , 4-benzyl- piperidino and 4-phenyl-l-pipera'zinyl . The compounds of formula (I) can be prepared by reacting a starting material of the formula 0 II R0C-C n H 2n -Ar-0CH 2 -Z (II) wherein, R, n and Ar are defined as above and Z is wherein Hal is a halogen atom, especially Cl or Br, with a primary amine of the formula NH 2 R χ (III) wherein R^ is defined as above. This process is pre¬ ferably carried out in the presence of an inert solvent, although it can be carried out in the absence of solvent While time and temperature are not critical factors, the reaction is generally conducted at a temperature from about room temperature to about 200°C (preferably from about 60 to 120°C), for a period of time from about 30 minutes to 24 hours. Suitable inert solvents include ethers such as dioxane, tetrahydrofuran and ethylene glycol monomethyl ether; aromatic hydrocar- bons such as benzene, toluene or xylene; lower alcohols such as methanol , ethanol and isopropanol; and esters such as ethyl acetate, dimethylformamide and di ethylsulfoxide. The process is frequently carried out in the presence of a basic compound, for example, an inorganic base such as sodium carbonate, sodium hydroxide, sodium bicarbonate, sodium amide or sodium hydride; or an organic base such as tri- ethylamine, tripropylamine, pyridine, quinoline, DBN (l,5-diazabiscyclo[4.3.0]non-5-ene), DBU(l,8-diazabi- cyclo[5.4.0]undec-7-ene) or Dabco (l,4-diazabicyclo[2.2.2 octane or triethylenediamine). The ratio of the amounts of reactants used can be selected over a wide range. It is, however, » generally desirable for the amine of formula (III) to be used in an equimolar- quantity or in an excess amount, preferably from an equimolar quantity to about seven times the molar quantity. The.starting materials of formula (II) can be conveniently prepared by reacting the corresponding compounds of the formula wherein R, n and Ar are defined as before, with an ep-ih ' alogenohydrin of the formula 4« „ (V) wherein Hal is a halogen atom, especially Cl or Br. This process can be carried out in the- presence of a suitable basic compound, for example an inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, sodium hydride, sodium metal, potassium metal or sodium amide, or an organic basic compound such as piperidine, pyridine, triethyla ine, DBN, DBU or Dabco, in the presence or absence of a solvent. Suitable solvents are, for example, a lower alcohol such as ethanol , ethanol or isopropanol; a ketone such as acetone; an ether such as dioxane, tetrahydrofuran or ethylene glycol monomethyl ether; or an aromatic hydrocarbon such as benzene, toluene or xylene. In this reaction, the epihalogenohydrin of formula (V) ordinarily can be used in an equimolar to excess quantity, preferably about 5 to 15 times the molar quantity of the formula (IV) starting material. The process can be conducted.at a temperature between about 0 and 150°C, preferably at from about 50 to about 100°C. Usually, the reaction product is a mixture of the corresponding (2,3-epoxy)propoxy and 3-halogeno- 2-hydroxypropoxy compounds encompassed by formula (II) and can be used as such to prepare the formula (I) compounds. The starting materials of formula (IV) can be prepared by esterification of carboxylic acids of the formula H00C-C n H 2n -Ar-0H (VI) wherein n and Ar are defined as before, or the cor¬ responding acid chlorides or acid anhyrides, by re- action with an alcohol of the formula ROH (VII) wherein R is defined as before. Reaction conditions, solvents and the like vary with the particular re- actants employed. Generally speaking, when an acid of formula (VI) is utilized as the starting material, the process is conducted in the presence of a con¬ ventional esterification catalyst, e.g. an inorganic acid such as hydrogen chloride gas, concentrated sul- furic acid, phosphoric acid, polyphosphoric acid, boron trifluoride or hypochlorous acid, or an organic acid such as trifluoroacetic acid, trifluoromethane¬ sulfonic acid, naphthalenesul fonic acid, p-toluene- sulfonic ' acid, benzenesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid anhydride, thionyl chloride, acetone dimethyl acetal and the like. A cation exchange resin may also be used as the catalyst The reaction can be carried out in the presence or absence of soTvent, at a temperature between about -20 to about 200°C, preferably between about 0 and about 150°C, for a period of time from about 10 minutes to about 20 hours. If a solvent is employed, an inert solvent is desirable, for example, an aromatic hydrocarbon such as benzene, toluene or xylene; a halogenated hydrocarbon such as chloroform, dichloromethane, dichloroetha-ne or carbon tetrachloride; or an ether such as diethyl ether, tetrahydrofuran, " dioxane or ethylene glycol monomethyl ether. The ratio of amount of a compound of formula ( VI) to an alcohol of the formula ROH is not subject to any specific restriction and may be suitably selected from a wide range. While usually it is desirable that the latter is used in an excess quantity in the absence of the solvent, in the presence of the solvent it is desirable that the latter is used in an equimolar to 5 times the molar quantity of the former, more preferably an equi¬ molar to 2 times the molar quantity of the former. This reaction can advantageously be effected by using a drying agent such as anhydrous calcium chloride, anhydrous cupric sulfate, . anhydrous calcium sulfate, phosphorus pentoxide or the like. Alternatively, an acid of formula (VI) can be converted to the corresponding salt of the type M T" 00C-C n K 2n -Ar-0H (VIII) where n and Ar are defined as before and M + is Na + or the like; that salt can then be reacted with a hal ide of the formula R-Hal (IX) where R is defined as before and Hal is halogen, pre- ferbaly Cl or Br, to afford the corresponding starting material of formula (IV). The compounds of the invention which contain a sulfinyl (SO) or sulfonyl (S0 2 ) group can be pre- pared by oxidation of the corresponding sulfur-con- taining compounds of the invention. Thus, for example, a compound of formula (I) wherein R is -CH 2 -X-R 2 where¬ in X is S can be treated with one equivalent of - chloroperbenzαic acid to afford the corresponding sulfinyl derivative, while treatment of the thio com- pound with two equivalents of m-chloroperbenzoic acid yields the corresponding sulfonyl derivative. Thus, the compounds of formula (I) wherein.R contains a sulfur atom, e.g. the compounds in which R is -CH 2 -X-R 2 or are de- fined above, are of value not only as soft β-adrenergic agents but also as chemical intermediates to the cor¬ responding soft drugs in which X is SO or S0 2 - The compounds of the present invention can also be prepared by esterification of the corresponding acid of the formula OH H00C-C n H 2n -Ar-0CH 2 CHCH 2 NHR 1 (X) wherein n, Ar and R. are defined as above, under con¬ ditions similar to the esterification of a compound of formula (VI) as described above. Equivalent to the compounds of formula (I) for the purposes of this invention are the corresponding acid addition salts formed with pharmaceutically acceptable acids. Illustrative of such acids are inorganic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid and the like; and organic acids such as acetic acid, oxalic acid, succinic acid, maleic acid, fu aric acid, malic acid, tartaric acid, citric acid, alonic acid, methanesulfonic acid, benzoic acid and the like. The compounds prepared by the procedures detailed above can easily be isolated and purified by usual separation means, e.g. solvent extraction, dilution, recrystallization, column chromatography or pre¬ parative thin-layer chromotography. The compounds of the present invention also in¬ clude their optical isomers. For therapeutic use, e.g. in the treatment of angina pectoris and arrhythmias, a compound of formula (I) or its salt can be conveniently administered in the form of a pharmaceutical composition containing the formula (I) compound or its salt and a pharma¬ ceutically acceptable carrier therefor. Suitable carriers vary with the desired form of the pharma¬ ceutical composition and may include diluents or ex- cipients such as fillers, binders, wetting agents, disintegrators, surface-active agents, lubricants and the like. The compound of the invention or its salt may be formulated together with the carrier into any desired unit dosage form. Typical unit dosage forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories; in- jectable solutions and suspensions are particularly preferred. -22- In the preparation of tablets, carriers which are widely used in this field can be employed, e.g. excipients such as lactose, sucrose, sodium chloride, glucose solution, urea, starch, calcium carbonate, kaolin, crystalline cellulose and silicic acid; binding agents such as water, ethanol, propanol , simple syrup, glucose, starch solution, gelatin solution, carboxy- methyl cellulose, shellac, methyl cellulose, calcium phosphate and polyvinylpyrrol idone; disintegrators such as dried starch, sodium alginate, agar-agar powder lamina! ia powder, sodium bicarbonate, calcium car¬ bonate, Tweens, sodium lauryl sulfate, stearic acid monoglyceride, starch and lactose; disintegration inhibitors such as sucrose, stearin, coconut butter and hydrogenated oil; absorption accelerators such as quaternary * ammonium bases and sodium lauryl sulfate; wetting agents such as glycerin and starch; adsorbing agents such as starch, lactose, kaolin, -bentonite and colloidal silicic acid; and lubricants such as purified talc, stearic acid salts, boric acid powder, Macrogol and solid polyethylene glycol . . In the preparation of pills, carriers which are known and widely used in this field can also be used, for example, excipients such as glucose, lactose, starch, coconut butter, hydrogenated vegetable oils, kaolin and talc; binders such as powdered gum arabic, powdered tragacanth, gelatin and ethanol; and dis¬ integrators such as la inaria and agar-agar. In the case of tablets, they can be further coated with the usual coating materials to make sugar-coated tablets, gelatin film-coated tablets, tablets coated with en¬ teric coatings, tablets coated with films or double- layered tablets and multi-layered tablets. In order to form suppositories, carriers which are known and widely used in this field can also be used, for example, polyethylene glycols, coconut but¬ ter, higher alcohols, esters of higher alcohols, gelatin and semi-synthesized glycerides. In order to prepare formulations suitable for injection, solutions and suspensions are sterilized and are preferably isotonic to blood. In making in- jectable preparations, carriers which are commonly used in this field can also be used, for example, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitane esters. In these instances, adequate amounts of sodium chloride, glucose or glycerin can be added to make the prep¬ arations isotonic. Furthermore, the usual dissolving agents, buf¬ fers, analgesic agents and preservatives can be added, as well as coloring materials, perfumes, seasoning agents, sweetening agents and other medi¬ cines, to the pharmaceutical compositions, if nec- essary or if desired. The amount of a compound of formula (I) or its acid addition salt to be present in the pharmaceutical composition, e.g. for use in treatment of angina pectoris and arrhythmias, can suitably be selected from a wide range, but usually 1 to 70% by weight of the total composition is preferable. As to the route of administration, e.g. for angina pectoris, same will vary with the particular composi¬ tion used. For example, tablets, pills, solutions, suspensions, emulsions, granules and capsules can be administered orally; and injectable preparations can be administered intravenously, either alone or mixed with injection transfusions such as glucose solutions and amino acid solutions. .If necessary, the injectable preparations can be administered separately, by the intramuscular, intracutaneous, subcutaneous or intraperitoneal route. The dosage of the compounds of the present in¬ vention is selected according to the usage, purpose and conditions of symptoms. For example, when these compounds are administered therapeutically to patients suffering from angina pectoris, hypertension, or un¬ expected arrhythmias during surgical operation, usually 0.5-6.0 mg/kg of the compound of general formula (I) or its acid addition salt may be administered. The present compounds also may be continuously administered at suitable intervals, including 30 min¬ utes to 60 minutes. The compounds of the present invention and their salts reduce intraocular pressure when applied to- pically/locally to the eye, thus are of particular use in the treatment of patients with glaucoma or in the treatment of other patients who require lowering of ocular pressure (such as patients with elevated intraocular pressure who may be at risk of developing glaucoma). The Instant compounds and their salts can be conveniently administered for these purposes by ■ 25 - formulating the selected β-blocker, in an effective intraocular pressure lowering amount, together with a non-toxic ophthalmically acceptable carrier therefor. Suitable carriers will be apparent to those skilled in the art of ophthalmic formulations. Obviously, the choice of suitable carriers will depend on the exact nature of the particular dosage form desired, e.g. whether the β-blocker is to be formulated into an ophthalmic solution or suspension (typically for use as eye drops), an ophthalmic ointment or cream or an ophthalmic gel. Preferred dosage forms are solutions, which contain a major amount of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters (e.g. a base such as NaOH), emulsifiers or dispersing agents, buf¬ fering agents, preservatives, wetting agents and jelling agents (e.g. methylcellulose) may also be pre¬ sent. Most preferably, the ophthalmic composition is a sterile, isotonic, uffered aqueous solution. Generally speaking, the ophthalmic composition con¬ taining the instant β-blockers may be prepared and may contain the various inert ingredients or carriers as previously described in the patent or non-patent literature as being suitable for ophthalmic co posi- tions comprising known β-blockers such as timolol and labetolol. The amount of the β-blocker of this in¬ vention which will be present in the ophthalmic com¬ position will of course vary with the particular β -blocker employed and the type of formulation selected. Generally speaking, the composition will contain 0.01 to 5% of a compound of formula (I), preferably 0.25 to 2.5%; in other words, each ml of solution will con- tain 0.1 to 50 mg, preferably 2.5 to 25 mg, of the free base. The dose administered ophthalmically will be selected according to the particular compound em¬ ployed and the size and condition of the patient, but in any event will be a quantity sufficient to cause a significant reduction in intraocular pressure. In order to further illustrate the present in¬ vention and the advantages thereof, ' specific examples of compounds of formula (I) are given below, it being understood that these . examples are intended only as illustrative and are not in any way limitative. Also exemplified below are the preparation of selected starting material ' s. In all the examples to follow- all melting points are uncorrected and were obtained by using electrothermal capillary melting point apparatus EXAMPLE 1 To a solution of 4-hydroxyρhenyl acetic acid (7.6 g, 0.05 mol) in ethanol (100 mL) was added potassium hydroxide (2.8 g, 0.05 mol), with stirring and ice cooling. The white crystalline potassium salt which was separated by fi 1 tration. mel ted at about 275-277°C and was obtained in 90.5% yield. The potassium salt of 4-hydroxyphenyl acetic acid (9.5 g, 0.05 mL) was suspended in dimethyl formamide (25 mL). Chloromethyl pivalate (7.53 g, 0.05 mol) was added and the reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate (100 mL). The ethyl acetate layer was washed, first with aqueous 5% NaHC0 3 (100 L) and then twice with water, then was dried over anhydrous MgSO^, filtered and evaporated to yield pi valyl oxymethyl 4-hydroxy- phenylacetate, melting at 159-161°C (yield 70.2%). EXAMPLE 2 Pivalyloxy ethyl 4-hydroxyphenylacetate (7.0 g, 0.05 mol) was dissolved in acetone (50 mL) and epi- chlorohydrin (40 mL) was added. That mixture was refluxed in the presence of DBU (1 mL, 0.007 mol) for 2 hours, then was allowed to stir at room temperature overnight. The reaction mixture was evaporated i va cuo. The epoxide residue was dissolved in acetonitrile (80 L), i sopropyl mi ne (20 mL, 0.23 mol ) -28- was added and the reaction mixture was stirred overnight at room temperature, refluxed for 4 hours and evaporated. The free amine base was purified by extraction with acid and base from ether. After evaporation of the ether, the residual oil was partitioned between ethyl ether and 1 aqueous KOH solution, the ether layer was washed with 1M HC1 , the acidic layer was basified with 1M aqueous KOH solution, and fresh anhydrous ethyl ether was added. The ether layer was separated, dried over anhydrous MgS0 and filtered. An equivalent amount of oxalic acid in acetone was added dropwise. The oxalate salt which separated was filtered and dried. It melted at.123- . 124°C. The free base, pivalyloxymethyl 4-(2-hydroxy-3- isopropyl ami no) prop xyphenyl acetate , has the structure: The identity of the product was confirmed by NMR and elemental analysis. -29- EXAMP L E 3 1-Adamantaneethaπol (10 g, 0.05 mol), 4-hydroxy- phenylacetic acid (8.43 g, 0.05 mol) and p-tol uenesul - fonic acid (1 g, 0.006 mol) were refluxed in benzene (100 mL) with continuous water separation for 8 hours, then allowed to stir overnight. The residue was washed, first with 5% aqueous sodium bicarbonate solution (50 mL) and then twice with water (50 mL) , then was dried over anhydrous MgS0 4 and filtered. The filtrate was concentrated in vacuo to give (adamant-1-yl )ethyl 4-hydroxyρhenyl acetate. (Adamant-1-yl )ethyl 4-hydroxyphenyl acetate was taken up in epichlorohydrin (50 mL) and refluxed for 2 hours in the presence of DBU (1 L, 0.007 mol) . The residue was dissolved in acetonitrile (100 L) and refluxed with isopropyl amine (20 L, 0.23 mol) for 4 hours. The reaction mixture was evaporated in vacuo and the residue was partitioned between ethyl ether (100 mL) and 0.5 N aqueous NaHC0 3 solution (100 mL) . The ether layer was separated and IN HCl (30 mL) was added to it. The aqueous layer was separated, 1M aqueous KOH solution (30 L) was added and the solution was extracted with ether (100 mL). The aqueous layer was discarded and the ether layer was dried over anhydrous MgS0 4 , filtered and evaporated in vacuo. The oily -30- product was dissolved in acetone (25 mL) and an equivalent quantity of oxalic acid in acetone (25 mL) was added dropwise, with stirring. The acetone was evaporated in vacuo and the residue was partitioned between ether (100 mL) and IM aqueous KOH solution (100 mL) . The ether layer was separated, dried over anhydrous MgS0 4 , filtered and concentrated in vacuo. The oily residue was dissolved in acetone (25 mL) and an equivalent amount of oxalic acid in acetone (25 mL) was added dropwise, with stirring. The product which separated was removed by filtration, dried and recrystall ized from acetone. The oxalate salt of (adamant-1-yl )ethyl 4-(2-hydroxy-3-isopropylamino)pro- poxyphenylacetate thus obtained melted at 95-97°C. Yield 70.9%. The free base has the structure: NMR and elemental analysis were consistent with the assigned structure. EXAMPLE 4 1-Adamantanemethanol (8.31 g, 0.05 mol), 4- hydroxyphenyl acetic acid (7.6 g, 0.05 mol) and p- toluenesulfonic acid (1 g, 0.006 mol) were refluxed in benzene (100 L) with continuous water separation for 8 hours. The reaction mixture was allowed to cool with stirring overnight, then was washed, .first with water (100 mL), then with aqueous 5% NaHC0 3 solution (100 mL), then twice more with water (100 mL). Drying over anhydrous MgS0 4 , filtering and concentrating in vacuo afforded (adamant-1-yl )methyl 4-hydroxypheπyl acetate, which was then combined with epichl orohydrin (50 mL) and refluxed for 2 hours in the presence of DBU (1 mL , 0.007 mol). Excess epichl orohydrin was removed in vacuo. The oily residue was dissolved in acetonitrile (100 mL) and combined with i sopropyl amine. (20 mL, 0.23 mol). The resultant reaction mixture was refluxed for 4 hours. The oily brown residue was partitioned between ethyl ether (100 mL) and IM aqueous KOH solution (100 L) . The ether layer was separated and to it was added IN HCl (30 mL) . The resultant acid layer was separated and to it were added ethyl ether (100 mL) and IM aqueous KOH solution (30 mL). The resultant ether layer was separated, dried over anhydrous MgS0 4 , filtered and evaporated in vacuo to give the free amine base as a crude product. The crude product (5.16 g, 72.5% yield) was dissolved in acetone (25 mL), and oxalic acid (1.8 g) in acetone (25 mL) was added dropwise, with stirring. The mixture was allowed to stir for 24 hours with additional acetone. The acetone solution was evaporated and the oily residue was partitioned between ether (100 mL) and IM aqueous KOH solution (100 mL) . The ether solution was dried over anhydrous MgS0 4 , filtered and concentrated. The oily residue was dissolved in acetone and an equivalent amount of oxalic acid in acetone was added dropwise. The oxalate salt of (adamant-1-yl )methyl 4-(2-hydroxy- 3-isopropyl aminojpropoxyphenyl acetate which separated w _ 1as removed and dried. It melted at 55-57°C. NMR and elemental analysis were consistent with structure. The free base has the formula: EXAMPLE 5 2-Norboranemethanol (6.34 g, 0.05 mol), 4-hydroxy- phenylacetic acid (7.6 g, 0.05 mol), p-tol ueπesul foni c acid (2 g, 0.006 mol) and benzene (100 L) were refluxed with continuous water separation for 8 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate (100 mL) and washed, first with 5% aqueous NaHC0 3 solution (100 mL) , then twice with water (200 L). Drying over anhydrous MgS0 4 , filtering and evaporation left an oily residue, identified by NMR as the desired (norborn-2-yl )methyl 4-hydroxyphenylacetate. That product was taken up in acetone (50 L), epichl orohydrin (40 mL) was added, and the reaction mixture was refluxed for 2 hours in the presence of DBU (2 mL , 0.007 mol). The reaction mix¬ ture was evaporated in vacuo and the residual oil was taken up in acetonitrile (100 mL). I sopropyl amine (20 mL, 0.23 mol) was added and the reaction mixture was refluxed for 4 hours, then evaporated to give the free amine base as an oil . The oil was dissolved in acetone (50 mL) and an equivalent amount of oxalic acid in acetone (25 L) was added dropwise with stirring. A white crystalline by-product melting at 198-200°C separated and was discarded. The acetone was evaporated in vacuo and the oil thus obtained was partitioned between ethyl ether (100 mL) and IM aqueous KOH solution (100 mL). The ether layer was separated and IM HCl (50 mL) was added. The acidic layer was separated, neutralized with IM aqueous KOH solution (50 L) and extracted with ethyl ether (100 mL). The ether layer was dried over anhydrous MgS0 4 , filtered and ■ 34 - evaporated to give the free amine base as an oil . Water (25 mL) was added to the oil; then oxalic acid (5.4 g, 0.01 mol) in acetone (25 mL) was added dropwise, with constant stirring. The oxalate salt of (norborn-2-yl ) ethyl 4-(2-hydroxy-3-i sop opy1 amino)- propoxyphenyl acetate which separated after cooling was washed with acetone (200 mL) and crystallized from a mixture of ethyl acetate and acetone. It melted at 68- 70°C. The corresponding free base has the structure: Elemental analysis and NMR were consistent with the assigned structure. EXAMPLE 6 The potassium salt of 4-hydroxyphenyl acetic acid (9.5 g, 0.1 mol) was taken up in a mixture of dimethyl sulfoxide (80 mL) and hexamethyϊphosphoramide (5.37 g, 0.1 mol). 2-Chloroacetamide (13.5 g, 0.3 mol) was added and the reaction mixture was first stirred at room temperature for 24 hours, then heated for 1 hour. The reaction mixture was evaporated, then cooled. The product which separated was taken up in ethyl acetate (150 mL), stirred, filtered and evaporated. The oily residue was partitioned between -35- ethyl acetate (100 mL) and water (100 mL). The organic layer was separated, dried over anhydrous MgS0 4 , filtered and evaporated to give the desired ester, carbamoylmethyl 4-hydroxyphenyl acetate, melting at 85- 87°C * , in 48.8% yield. Carbamoylmethyl 4-hydroxyphenyl acetate (10.4 g, 0.01 mol) was taken up in acetone. Epi chl orohydrin (40 mL) was added and the reaction mixture was refluxed for 2 hours in the presence of DBU (2 mL, 0.014 mol). The mixture was then evaporated to give an oil , which was dissolved in acetonitrile (100 mL) and then refluxed with i sopropylamine (20 mL , 0.23 mol) for 4 hours. The resultant mixture was evaporated in vacuo to give the desired free amine base as an oil . That oil was dissolved in acetone and an equivalent amount of oxalic acid in acetone was added. The acetone solution was • concentrated and then partitioned between ethyl ether (100 mL) and IM aqueous KOH solution (50 mL) . The ether layer was separated and extracted with IM HCl (50 mL) . The resultant acidic solution was neutralized with IM aqueous KOH solution and extracted with ethyl ether. The ether layer was separated, dried over anhydrous MgS0 4 , filtered and evaporated. The residue was dissolved in acetone and an equivalent amount of oxalic acid in acetone was added. The oxalate salt of carbamoylmethyl 4-(2-hydroxy-3-i sopropylamino)- propoxyphenylacetate which separated after cooling was removed by filtration and dried. It melted at 93- 95°C. The corresponding free base has the structural formula: NMR and elemental analysis were consistent with the assigned structure. ■ EXAMPLE 7 Use of the starting materials indicated below in the general esterification procedure described in Example 3, first paragraph, affords the indicated products: -4G- IΛ o •_§* ° o CM IΛ to oo en o fΛ EM H00C-C_,H 2rt -Ar-0H R0OC-C n H 2n -Ar-QH CH 3 CH 2 0CCH 2 0H CH 3 CH 2 0CCH 2 OCCH 2 (32) CH 3 SCH 2 0H HOOCCHo 2 Cv.Hn 2 ■ - OH CH 3 SCH 2 O0CCH 2 CH 2 -o OH (33) EXAMPLE 8 Substitution of an equivalent quantity of the products of Example 7 in the general procedures of Example 3, second paragraph [i.e. reaction of a compound of the formula ROOC-C H 2r) -Ar-0H with an epi hal ogenohydri n such as epi chlorohydrin , followed by reacting the resulant intermediate^ ) with the appropriate primary amine] affords, after appropriate isolation, the following compounds of the invention: SWUM mTE l RθC-C n H 2n -Ar " OCH 2 CHCH 2 NHR 1 (2) ( AN ANALOGUE OF ALPRENOLOL) STARTING MATERIAL R0C-C n H 2r -Ar-OCH^HC^NHR! (AN ANALOGUE OF ALPRENOLOL) (6) (AN ANALOGUE OF BUNOLOL) STARTING MATERIAL R0C-C Λ H 2n -Ar-0CH 2 CHCH 2 NHR I (AN ANALOG OF STARTIHC MATERIAL (AN ANALOGUE OF XIPRANOLOL) (AN ANALOGUE OF METOPROLOL) OH STARTING MATERIAL R0C-C n H 2n -Ar-0CH 2 CHCH 2 NHR I to OCCH. -o OH (19) 0CCH 2 0CH 2 ?HCH 2 NHCH(CH 3 )i (AN ANALOGUE OF METOPROLOL) STARTING HATFRIAI ,9 9 H R0C-C n H 2n -Ar-QCH 2 CHCH 2 NHR 1 00CCH 2 Ar 00CCH HCH(CH 3 ) 2 (AN ANALOGUE OF METOPROLOL) 9 9 H STARTING MATERIAL R0C-C n H 2n -Af-0CH 2 CHCH 2 NHR 1 r ~ 0 ~ /-r - l — - V-0 0CCHH 22 CCHHCCH 2 NHCH(CH 3 ) 2 (25) (AN ANALOGUE OF METOPROLOL) (AN ANALOGUE OF BUFUROLOL) OH START W, HATER1AL Rθ(:-C n H 2n -Ar-OCH 2 ( .HCH 2 NHR 1 (AN ANALOGUE OF PINOOLOL) (AN ANALOGUE OF METOPROLOL) P, OH STARTING MATERIAL R0C-C n H 2n -Ar-0CH 2 CHCH 2 NHR 1 (AN ANALOGUE OF PROPRANOLOL) (32) (AN ANALOGUE OF ACEBUTOLOL) β 9 H STARTING MATERIAL R0C-C n H 2n -Ar-0CH 2 CHCH 2 NHR 1 HCH(CH 3 ) 2 (AN ANALOGUE OF ATENOLOL; ALSO OF METOPROLOL) (AN ANALOGUE OF PRACTOLOL) STARTING MΛTfflfAi ROC-C^n-Ar- Q CH^HCH HR! Λ V H 2 0?- ' V-OCH 2 CHCH2NHCH(CH 3 )i (AN ANALOGUE OF METOPROLOL) (AN ANALOGUE OF METOPROLOL) jrv- CH 2 CH 2 OK-C' V OH (37) (AN ANALOGUE OF METOPROLOL) EXAMPL E 9 Treatment of the sulfur-containing compounds of the invention listed below with one equivalent of m-chloroperbenzoic acid affords the corresponding sulfinyl derivatives of the invention, while treat¬ ment of the thio compounds with two equivalents of m-chloroperbenzoic acid yields the corresponding sulfonyl derivatives of the invention. While the invention has been described in terms of various preferred embodiments, the skilled artisan will appreciate that various modifications, sub- substitutions, omissions and additions may be made withou departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims.

Claims: WHAT IS CLAIMED IS: A compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein: n is an integer from 0 to 10 inclusive; R is C 6 -C 12 cycloalkyl-C p H 2 p- wherein p is 0, 1 , 2 or 3; Cg-C 18 polycycl oal kyl -C p H 2p - wherein p is defined as above; Cg-C-^g polycycl oal kenyl -C p H 2 - wherein p is defined as above; Cg-C 1 cycloal kenyl -C p H 2p - wherein p is defined as above; -CH 2 -X-R 2 wherein X is S, SO or S0 and R 2 is C-1-C7 alkyl or C 3 -C-, 2 cycloalkyl; + I 3 -CH 2 -S-R 2 wherein R -is defined as .above; -CH-X-R4 CH 3 wherein X is defined as above, and wherein R3 is C^-Cy alkyl and R 4 is C^-Cy alkyl or wherein R 3 and R^ taken together represent -(CH 2 ) m - wherein m is 3 or 4 and -(CH 2 ) m - is optionally substituted by one to three C^-Cy alkyl; -CH-OCORg wherein Rg is hydrogen or CJ-CJ alkyl and R 6 is unsubstituted or substituted C-^- Cy alkyl, C 3 -C 12 cyclo ' alkyl , C 3 -C 12 cycloalkenyl or C - C3 alkenyl , the substituents being selected from the group consisting of halo, C-^-C j alkoxy, C-^-Cy alkyl¬ thio, C- Cy alkylsulfinyl, C^Cy al kyl sul fonyl , alkyl) and alkyl), or Rg is substituted or unsubstituted phenyl or benzyl , the substituents being selected from the group consisting of C^-Cy alkyl, C j -C 7 alkoxy, halo, carba oyl , C 2 -Cg alkoxycabonyl , C 2 -C 8 al kanoyloxy., C^Cy haloalkyl, mono C j -Cy al kyl )amino, di(C 1 -C 7 alkyl)amino, mono(C 1 - C 7 alkyl )carbamoyl , di(C 1 -C 7 al kyl ) carbamoyl , C 1 -C 7 alkylthio, C- i -C 7 alkylsulfinyl and C 1 -C 7 al kyl sul fonyl ; - ICsH-COORg wherein R g and R g are defined as above; or -CH-C0NR 7 R g wherein R g is defined as above and R 7 and Rg, which can be the same or different, are each hydrogen, ~ι~~~ alkyl , C 3 -C 12 cycloalkyl , phenyl or benzyl, or R 7 and R g are combined such that -NR 7 R g represents the residue of a saturated monocyclic secondary amine; R χ is C 1 -C 7 alkyl ; and Ar is a divalent radical containing at least one aromatic nucleus; with the proviso that when the divalent radical represented by Ar is unsubstituted phenylene, then R cannot be Cg-C 1 cycl oal kyl -C p H 2 - wherein p is defined as above. 2. A compound as defined by Claim 1, wherein R is Cg-C 12 cycl oal kyl-CpH 2p - having 6 to 8 ring atoms and bearing 0 to 4 methyl substituents and p is zero or one. 3. A compound as defined by Claim 2, wherein R is cycl ohexyl . 4. A compound as defined by Claim 2, wherein R is 2,6-dimethylcyclohexyl or 3,3,5,5-tetramethyl cycl o- hexyl . 5. A compound as defined by Claim 1, wherein R is C 6 -C 18 polycycl oal yl-CpH 2p - consisting of a two or three ring bridged saturated alicyclic hydrocarbon system bearing zero, one or two methyl substituents and having a total of 6 to 18 carbon atoms in the poly- cycloalkyl portion and p is zero, one or two, or wherein R is Cg-C^g polycycloal kenyl-C p H 2p - consisting of a two or three ring bridged unsaturated alicyclic hydrocarbon system bearing zero, one or two methyl substituents and having a total of 6 to 18 carbon atoms in the polycycl oal kenyl portion and p is zero, one or t o. 6. A compound as defined by Claim 5, wherein R is adamantyl, bornyl , norbornyl , adamantylmethyl , adamantylethyl, norbornylmethyl , norbornyl ethyl or norbornen 1 , preferably wherein R is (adamant-1- yl)ethyl, (adamant-1 -yl )methyl or (norborn-2-yl )methyl . 7. A compound as defined by Claim 1, wherein R is - wherein R 5 , Rg, R 7 and R Q are as defined in Claim 1. 8. A compound as defined by Claim 7, wherein Rg is hydrogen and R g is C 1 -C 7 alkyl. 9. A compound as defined by Claim 7, wherein R is pivalyl oxymethyl or carbamoylmethyl. 10. A compound as defined by Claim 1, wherein n is zero, one or two. 11. A compound as defined by Claim 1, wherein Ar comprises a phenylene grouping. 12. A compound as defined by Claim 11, wherein Ar is unsubstituted phenylene. 13. A compound as defined by Claim 12, wherein Ar is 1 ,4-phenylene or 1 ,3-phenylene. 14. A compound as defined by Claim 11, wherein Ar is phenylene substituted by C -C 7 alkyl , C^-C 7 alkyl-0- C 1 -C 7 alkylene-, Cg-Cg alkenyl , C-^- C j alkyl-S-, C 2 -Cg alkenyl-0-, C 3 -C 12 cycloalkyl , C -C- alkyl-CONH-, C 1 -C alkyl-CO- or H 2 NC0-C j -C 7 al kyl ene- , especial ly when Ar , 15. A compound as defined by Claim 1, wherein Ar is a divalent fused ring system containing two or three rings and optionally containing one or two hetero ring atoms selected from the group consisting of N, 0 and S, especially when Ar comprises a radical of the formula 16. A compound as defined by Claim 15, wherein Ar radical of the formula 17. A compound as defined by Claim 1, wherein Ar comprises a divalent ρhen l-C!-C 3 alkylene-phenyl radical , especially when Ar comprises a I phenylene-Cι*-C 3 alkylene-phenyl radical . 18. A compound as, defined by Claim 17, wherein Ar is a radical of the formula 19. A compound as defined by Claim 1 , wherein 0 the R0C-C n H 2n - grouping replaces a hydrogen atom on the corresponding ring of a known β-blocker, the structure of the compound of formula (I) being in all other respects identical to the structure of a known β- blocker. 20. A compound as defined by Claim 19, wherein the known β-blocker is metoprolol , bufurolol, al- prenolol, bunolol , xipranolol , nadolol , tiprenolol , oxprenolol , penbutolol, pindolol, carteolol, pro- pranolol , acebutolol , atenolol or practolol . 21. A compound as defined by Claim 1, wherein the n - grouping replaces a non-critical substituent on the corresponding ring of a known β-blocker, the structure of the compound of formula (I) being in all other respects identical to the structure of a known β-blocker. 22. A compound as defined by Claim 21, wherein the non-critical substituent is a lower alkyl or lower al kyl-0-lower alkylene substituent, especially when the non-critical substituent is a CH 3 -, CH CH - or CH 3 0CH 2 CH 2 - substituent. 23. A compound as defined by Claim 22, wherein the known β-blocker is metoprolol , bufurolol or xipranol ol . 24. A compound as defined by Claim 21 , wherein the non-critical substituent is a lower alkyl-CONH- or H 2 NC0-lower alkylene- substituent, especially when the non-critical substituent is a CH 3 CH 2 CH 2 C0NH-, 0 CH 3 C0NH- or H 2 NCCH 2 - substituent. 25. A compound as defined by Claim 24, wherein the known β-blocker is acebutolol , atenolol or practolol . 26. A compound as defined by Claim 1, wherein R-^ is isopropyl or tert-butyl . 27. A compound as defined by Claim 1, which is cyclohexyl 4-(2-hydroxy-3-i sopropy! amino) propoxy- phenylacetate, 2,6-dimethylcyclohexyl 4-(2-hydroxy-3- isopropyl amino) propoxyphenyl acetate or 3,3 ,5,5-tetra- methyl cyclohexyl 4-(2-hydroxy-3-i sopropy! ami no) pro¬ poxyphenyl acetate, or a pharmaceutically acceptable acid addition salt of one of said compounds. 28. A compound as defined by Claim 1, ' which is (adamant-1-yl )ethyl 4-(2-hydroxy-3-i sopropyl ami no)- propoxyphenylacetate, (adamant-X-yl )methyl 4-(2- hydroxy-3-i sopropyl amino)propoxyphenylacetate or (norborn-2-yl )methyl 4-(2-hydroxy-3-isopropyl amino)- propoxyphenyl acetate, or a pharmaceutically acceptable acid addition salt of one of said compounds. 29. A compound as defined by Claim 1, which is pival lox et yl 4-(2-hydroxy-3- sop opyl amino)pro- poxyphenyl acetate or carbamoylmethyl 4-(2-hydroxy-3- i sopropyl amino)propoxyphenyl acetate, or a pharma¬ ceutically acceptable acid addition salt of one of said compounds . 30. An oxalate salt of a compound as defined by any one of Claims 1 to 29. 31. A pharmaceutical composition of matter com¬ prising a compound of formula (I) as defined by Claim 1, or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic pharmaceutically acceptable carrier therefor; especially a pharmaceutical com¬ position of matter, in unit dosage form, for use in eliciting a β-adrenergic blocking response in a warm¬ blooded animal , said composition comprising, per dosage unit, an effective unit β-adrenergic blocking amount of a compound of formula (I) as defined by Claim 1 or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic pharmaceutically acceptable carrier therefor. 32. An ophthalmic composition of matter com- prising a compound of formula (I) as defined by Claim 1, or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic ophthalmically acceptable carrier therefor; especially an ophthalmic composition of matter, in unit dosage form, for use in the treat¬ ment of glaucoma in a warm-blooded animal, said composition comprising, per dosage unit, an effective unit intraocular pressure decreasing amount of a compound of formula (I) as defined by Claim 1 or a pharmaceutically acceptable acid addition salt thereof, and a non-toxic ophthalmically acceptable carrier therefor.

Inventors: BODOR NICHOLAS S, BODOR, NICHOLAS, S.
Applicants: BODOR NICHOLAS S, BODOR, NICHOLAS, S.
Application year: 1985
Main classification: C07C93
IPC codes: A61K31, A61P9, A61P25, A61P27, C07C217, C07D209, C07D215, C07D307